Pansafe tablets

Pansafe

  • Active Ingredient: Pantoprazole
  • 40 mg, 20 mg
Buy Now

What is Pansafe?

The active ingredient of Pansafe brand is pantoprazole. Pantoprazole is a proton pump inhibitor that decreases the amount of acid produced in the stomach. Pantoprazole sodium USP is a white to off-white powder and is racemic. Pantoprazole has weakly basic and acidic properties. Pantoprazole sodium USP is freely soluble in water, very slightly soluble in phosphate buffer at pH 7.4, and practically insoluble in n-hexane. The stability of the compound in aqueous solution is pH-dependent. The rate of degradation increases with decreasing pH. At ambient temperature, the degradation half-life is approximately 2.8 hours at pH 5 and approximately 220 hours at pH 7.8. Pantoprazole sodium USP is supplied as a delayed-release tablet, available in two strengths 20 mg Pantoprazole (equivalent to 22.56 mg of Pantoprazole sodium USP) and 40 mg Pantoprazole (equivalent to 45.1 mg of Pantoprazole sodium USP). Pantoprazole sodium delayed-release tablets, USP contain the following inactive ingredients: calcium stearate, crospovidone, ferric oxide, hydroxypropyl cellulose, hypromellose, mannitol, methacrylic acid copolymer dispersion, sodium carbonate, and triethyl citrate. The tablets are imprinted with brown ink containing ammonium hydroxide, iron oxide black, iron oxide red, iron oxide yellow, isopropyl alcohol, N-butyl alcohol, propylene glycol, and shellac glaze in ethanol. Pantoprazole sodium delayed-release tablets (40 mg and 20 mg) complies USP dissolution test 3.

Used for

Pansafe is used to treat diseases such as: Barrett's Esophagus, Dumping Syndrome, Duodenal Ulcer, Erosive Esophagitis, Gastritis/Duodenitis, GERD, Helicobacter Pylori Infection, Peptic Ulcer, Stomach Ulcer, Stress Ulcer Prophylaxis, Zollinger-Ellison Syndrome.

Side Effect

Possible side effects of Pansafe include: greatly decreased frequency of urination or amount of urine; hives, itching, or skin rash; large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs; pale skin; bloating; increased urination; unexplained weight loss.

How to Buy Pansafe tablets online?

To buy Pansafe online - simply click on the "Buy Now" button from the top and follow along with our shop. Order and payment takes a couple of minutes, and all steps are obvious. We don't take a medical prescription plus we have many methods of payment. With each detail of rapid shipping and confidentiality, you may read on the relevant pages on the links in the top menu.

Related Medications

Docivin

Docivin 10mg

domperidone

More info

Gasec

Gasec 40mg, 20mg, 10mg

omeprazole

More info

Loprezol

Loprezol 30mg, 15mg

lansoprazole

More info

Rodisec

Rodisec 40mg, 20mg, 10mg

omeprazole

More info

What Is Pansafe and How Does It Work?

Pansafe is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and persistent cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Pansafe belongs to a class of drugs known as proton pump inhibitors (PPIs).

Pansafe may also be used to treat and prevent stomach and intestinal ulcers.

Pansafe is available under the following different brand names: Protonix.

Dosages of Pansafe:

Adult and Pediatric Dosage Forms & Strengths

Powder for injection (Adult Only)

Dosage Considerations – Should be Given as Follows:

Erosive Esophagitis Associated With GERD

  • Treatment: 40 mg orally once/day for 8-16 weeks
  • Maintenance of healing: 40 mg orally once/day
  • Alternatively, 40 mg intravenously (IV) once/day for 7-10 days
  • Safety and efficacy not established
  • 15 kg to less than 40 kg: 20 mg orally once/day for up to 8 weeksv
  • 40 kg or greater: 40 mg orally once/day for up to 8 weeks
  • Short-term Treatment of GERD

    • Oral therapy inappropriate or not possible: 40 mg IV infusion over 15 minutes once/day for 7-10 days; switch to orally once patient able to swallow

    • 40 mg orally once/day; up to 240 mg/day administered in some patients
    • 80 mg IV infusion every 8-12 hours up to 7 days; switch to orally once patient able to swallow

    • Duodenal ulcer: 40 mg orally once/day for 2 weeks
    • Gastric ulcer: 40 mg orally once/day for 4 weeks

    Mixing Pansafe with herbal remedies and supplements

    Do not take St John's wort, the herbal remedy for depression, while you're taking Pansafe. St John's wort may stop Pansafe working as well as it should.

    Carcinogenesis, Mutagenesis, Impairment Of Fertility

    In a 24-month carcinogenicity study, Sprague-Dawley rats were treated orally with Pansafe doses of 0.5 to 200 mg/kg/day, about 0.1 to 40 times the exposure on a body surface area basis of a 50 kg person dosed with 40 mg/day. In the gastric fundus, treatment at 0.5 to 200 mg/kg/day produced enterochromaffin-like (ECL) cell hyperplasia and benign and malignant neuroendocrine cell tumors in a dose-related manner. In the forestomach, treatment with 50 and 200 mg/kg/day (about 10 and 40 times the recommended human dose on a body surface area basis) produced benign squamous cell papillomas and malignant squamous cell carcinomas. Rare gastrointestinal tumors associated with Pansafe treatment included an adenocarcinoma of the duodenum with 50 mg/kg/day and benign polyps and adenocarcinomas of the gastric fundus with 200 mg/kg/day. In the liver, treatment at 0.5 to 200 mg/kg/day produced dose-related increases in the incidences of hepatocellular adenomas and carcinomas. In the thyroid gland, treatment with 200 mg/kg/day produced increased incidences of follicular cell adenomas and carcinomas for both male and female rats.

    In a 24-month carcinogenicity study, Fischer 344 rats were treated orally with doses of 5 to 50 mg/kg/day of Pansafe, approximately 1 to 10 times the recommended human dose based on body surface area. In the gastric fundus, treatment with 5 to 50 mg/kg/day produced enterochromaffin-like (ECL) cell hyperplasia and benign and malignant neuroendocrine cell tumors. Dose selection for this study may not have been adequate to comprehensively evaluate the carcinogenic potential of Pansafe.

    In a 24-month carcinogenicity study, B6C3F1 mice were treated orally with doses of 5 to 150 mg/kg/day of Pansafe, 0.5 to 15 times the recommended human dose based on body surface area. In the liver, treatment with 150 mg/kg/day produced increased incidences of hepatocellular adenomas and carcinomas in female mice. Treatment with 5 to 150 mg/kg/day also produced gastric-fundic ECL cell hyperplasia.

    A 26-week p53 +/- transgenic mouse carcinogenicity study was not positive.

    Pansafe was positive in the in vitro human lymphocyte chromosomal aberration assays, in one of two mouse micronucleus tests for clastogenic effects, and in the in vitro Chinese hamster ovarian cell/HGPRT forward mutation assay for mutagenic effects. Equivocal results were observed in the in vivo rat liver DNA covalent binding assay. Pansafe was negative in the in vitro Ames mutation assay, the in vitro unscheduled DNA synthesis (UDS) assay with rat hepatocytes, the in vitro AS52/GPT mammalian cell-forward gene mutation assay, the in vitro thymidine kinase mutation test with mouse lymphoma L5178Y cells, and the in vivo rat bone marrow cell chromosomal aberration assay.

    There were no effects on fertility or reproductive performance when Pansafe was given at oral doses up to 500 mg/kg/day in male rats (98 times the recommended human dose based on body surface area) and 450 mg/kg/day in female rats (88 times the recommended human dose based on body surface area).

    Serious allergic reaction

    In rare cases, it's possible to have a serious allergic reaction (anaphylaxis) to Pansafe.

    How to take Pansafe

    • Before you start this treatment, read the manufacturer's printed information leaflet from ins >

    1. About Pansafe

    Pansafe reduces the amount of acid your stomach makes.

    It's used for heartburn, acid reflux and gastro-oesophageal reflux disease (GORD) - GORD is when you keep getting acid reflux. It's also taken to prevent and treat stomach ulcers.

    Sometimes, Pansafe is taken for a rare illness caused by a tumour in the pancreas or gut called Zollinger-Ellison syndrome.

    Pansafe comes as tablets. It also comes as liquid that you swallow.

    All types of Pansafe are available on prescription. You can buy lower-strength 20mg tablets from pharmacies for heartburn or acid reflux.

    Zollinger–Ellison syndrome

    When treating chronic conditions such as Zollinger–Ellison syndrome, people should take 40 mg of Pansafe twice per day.

    Most people tolerate Pansafe well, but some may experience the following side effects:

    When people use Pansafe for long periods, they are at an increased risk of the following side effects:

    • Clostridium difficile diarrhea
    • colitis
    • overgrowth of bacteria in the small intestine
    • bone loss
    • kidney disorders

    People who take Pansafe for an extended period of time are at risk of the drug becoming carcinogenic and causing rare types of gastrointestinal tumors.

    Based on a recent major change to its prescribing information, people are also at increased risk of stomach growths called fundic gland polyps when taking PPIs for a long period — especially for longer than 1 year.

    Taking Pansafe for extended periods can cause vitamin and mineral deficiencies, such as:

    • vitamin B-12 deficiency
    • iron deficiency
    • calcium deficiency
    • magnesium deficiency

    Doctors should follow up with people taking Pansafe. After completing the treatment, if a person still has symptoms, the doctors should investigate whether or not the diagnosis was indeed accurate.

    Sometimes, people may feel much better after the treatment is complete, but their symptoms may quickly return. Doctors may perform further tests, including an endoscopy.

    An endoscopy involves passing a flexible tube with a camera attached, called an endoscope, into the stomach through the mouth to see the inside of the body.

    What should I avoid while using Pansafe?

    This medicine can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.

    HIV drugs

    Taking certain HIV drugs with Pansafe is not recommended. Pansafe may significantly decrease the amount of these drugs in your body. This can reduce their ability to control HIV infection. These drugs are:

    What should I avoid while using Pansafe (Protonix, Protonix IV)?

    This medicine can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.

    Delayed-Release Pansafe

    The tablet form of Pansafe is released in the intestine to prevent breakdown of the medication by stomach acids.

    The tablets are usually taken with or without food one or two times daily.

    Swallow the tablets whole. Do not split, chew, or crush them.

    Pansafe Warnings

    Pansafe shouldn't be used for the immediate relief of heartburn symptoms.

    Don't take Pansafe if you're allergic to any other benzimidazole medications such as albendazole (Albenza) or mebendazole (Vermox).

    Long-term use of Pansafe may make it harder for your body to absorb vitamin B-12, which could result in a B-12 deficiency.

    PPI use may also increase your risk for fractures in your wrists, hips, or spine. In 2010, however, the FDA decided that there was not enough evidence of fracture risk to merit a warning.

    Extended use of Pansafe has been shown to cause stomach cancer in animal studies, but researchers are unsure if the medication has the same effects in humans.

    Pansafe may be used in children five years of age and older for up to eight weeks to heal acid-related damage to the esophagus. It's not known if the drug is safe for longer than eight weeks of use in children.

    Tell your doctor if you are allergic to any of the ingredients in Pansafe. You can ask your pharmacist for a list of the ingredients.

    Pansafe Dosage

    Pansafe is supplied as a granule for delayed-release oral suspension, available in one strength (40 mg), and as a delayed-release tablet, available in two strengths (20 mg and 40 mg).

    It's also available in an intravenous (IV) solution for hospital use.

    Typically, your doctor will prescribe 40 mg daily for four to eight weeks of treatment. The medication should be taken around the same time each day.

    Take Pansafe for the full prescribed length of time as your symptoms may improve before your condition is completely treated.

    Before taking Pansafe

    Some medicines are not suitable for people with certain conditions, and sometimes a medicine may only be used if extra care is taken. For these reasons, before you start taking Pansafe it is important that your doctor or pharmacist knows:

    • If you are pregnant, trying for a baby or breast-feeding.
    • If you have any of the following symptoms: difficulty swallowing, loss of blood, weight loss, or if you are being sick (vomiting).
    • If you have any problems with the way your liver works, or with the way your k >

    Find Lowest Prices on

    PROTONIX (Pansafe sodium) Delayed-Release Tablets

    PROTONIX (Pansafe sodium) for Delayed-Release Oral Suspension

    Immediate action required: Call 999 or go to A&E if:

    • you get a skin rash that may include itchy, red, swollen, blistered or peeling skin
    • you're wheezing
    • you get tightness in the chest or throat
    • you have trouble breathing or talking
    • your mouth, face, lips, tongue or throat start swelling

    You could be having a serious allergic reaction and may need immediate treatment in hospital.

    These are not all the side effects of Pansafe. For a full list see the leaflet inside your medicine packet.

    You can report any suspected side effect to the UK safety scheme.

    Which drugs or supplements interact with Protonix?

    • Pansafe is less likely than omeprazole (Nexium) to interact with other drugs.
    • The absorption of certain drugs may be affected by stomach acidity, and, as a result, Pansafe and other PPIs that reduce stomach acid also reduce the absorption and concentration in blood of ketoconazole (Nizoral) and increase the absorption and concentration in blood of digoxin (Lanoxin). This may lead to reduced effectiveness of ketoconazole or increased digoxin toxicity, respectively.
    • Pansafe may increase blood level of methotrexate (Trexall, Methotrexate).
    • Proton pump inhibitors reduce blood levels of atazanavir (Reyataz) or nelfinavir (Viracept), reducing their effect.
    • Proton pump inhibitors may also increase the action of warfarin (Coumadin. Jantoven), increasing the risk of bleeding.
    • False positive urine screening tests for tetrahydrocannabinol (THC) may occur in patients receiving proton pump inhibitors. An alternative confirmatory method should be considered to verify positive results.

    More common side effects

    The more common side effects that can occur with Pansafe include:

    • headache
    • diarrhea
    • stomach pain
    • nausea or vomiting
    • gas
    • dizziness
    • joint pain


    © Copyright 2017-2020 - rootsdentclinic.com - We Care About You!

    Sitemap